CVS Q4 Deep Dive: Pharmacy Turnaround and Regulatory Shifts Shape Outlook

Diversified healthcare company CVS Health (NYSE:CVS) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 8.2% year on year to $105.7 billion. Its non-GAAP profit of $1.09 per share was 9.4% above analysts’ consensus estimates.

Is now the time to buy CVS? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

CVS Health’s fourth quarter results reflected steady execution across its pharmacy, health services, and insurance businesses, with management crediting improvements in operational efficiency and customer experience as key drivers. CEO David Joyner highlighted the completed transition to a cost-based reimbursement model and successful integration of Rite Aid assets as important milestones, noting, “We have successfully completed the transition to a cost-based reimbursement. This was a significant step in creating a more transparent and stable pharmacy market.” The quarter also saw robust same-store sales growth, attributed to prescription volume and enhanced consumer engagement.

Looking ahead, CVS Health’s guidance for 2026 centers on disciplined cost management, evolving regulatory dynamics, and further investments in technology and consumer experience. Management emphasized the importance of adapting to new regulations in its pharmacy benefits business and advancing its open engagement platform. CFO Brian Newman cautioned that, while medical cost trends remain elevated, “our experience in 2025 is supportive of our trend assumptions underlying our guidance.” The company expects stable but cautious performance in Medicaid and ongoing efforts to recover Medicare Advantage margins, with innovation and partnerships remaining focal points for growth.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to operational improvements in pharmacy services, better-than-expected commercial membership retention, and advances in digital engagement.

• Pharmacy transformation progress: CVS Health completed the shift to a cost-based reimbursement model across commercial, Medicare, and Medicaid lines, which management believes will support transparent and durable margins going forward.
• Rite Aid integration impact: The acquisition of select Rite Aid assets brought 9 million new patients and expanded CVS’s national footprint, helping drive prescription volume growth and improved pharmacy script share.
• PBM regulatory adaptation: Leadership highlighted that recent and anticipated pharmacy benefit manager (PBM) legislation aligns with its existing TrueCost model, which focuses on transparency and pass-through rebates. Management expects these regulatory shifts to accelerate TrueCost adoption but does not anticipate material long-term margin compression in the PBM segment.
• Commercial membership resilience: The insurance business saw stronger-than-expected retention in commercial group accounts, with innovative technology and solutions resonating among sophisticated purchasers of healthcare benefits. Management noted this was a key factor in the segment’s solid performance despite broader industry pressures.
• Technology and AI investments: CVS Health continued to invest in its open engagement platform and artificial intelligence tools to improve consumer experience, operational efficiency, and integration across its pharmacy and insurance offerings. These initiatives are expected to yield future cost savings and support product innovation.

Drivers of Future Performance

CVS Health’s outlook is influenced by regulatory changes, evolving payer dynamics, and ongoing investments in technology and consumer engagement.

• Regulatory and policy environment: Management flagged proposed Medicare Advantage rate changes and PBM reforms as key factors for the coming year, stating that while preliminary rates are disappointing, the company remains committed to margin recovery in its Aetna business. Advocacy efforts with CMS and lawmakers are ongoing to secure more sustainable funding for Medicare Advantage.
• Cost discipline and margin focus: The company expects continued improvement in Medicare Advantage and commercial insurance margins through disciplined pricing, product mix optimization, and risk adjustment efforts. Medicaid performance is expected to remain stable but cautious given broader industry trends and rate pressures.
• Digital and consumer innovation: Ongoing investments in CVS’s open engagement platform and AI-powered tools are aimed at driving higher consumer engagement, reducing costs, and enabling new health services. Management believes these technology initiatives are critical for long-term competitiveness and customer loyalty.

Catalysts in Upcoming Quarters

Looking forward, the StockStory team will be watching (1) progress on regulatory and policy developments affecting Medicare Advantage and PBM transparency, (2) CVS’s ability to maintain and grow commercial membership through product innovation, and (3) the pace of adoption and monetization of the open engagement platform and AI-driven initiatives. Execution in pharmacy integration and cost-based reimbursement models will also serve as critical indicators of CVS Health’s ability to deliver on its multi-year objectives.

CVS Health currently trades at $75.72, in line with $75.77 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.